References
- I. Klein, B. Sarkadi, and A. Varadi, "An inventory of the human ABC proteins", Biochim. Biophys. Acta., Vol. 1461, pp. 237-262, 1999. https://doi.org/10.1016/S0005-2736(99)00161-3
- T. Fojo, and S. Bates, "Strategies for reversing drug resistance", Oncogene, Vol. 22, pp. 7512-7523, 2003. https://doi.org/10.1038/sj.onc.1206951
- A. Bodo, E. Bakos, F. Szeri, A. Varadi, and B. Sarkadi, "The role of multidrug transporters in drug availability, metabolism and toxicity", Toxicol. Lett., Vol. 140, pp. 133-143, 2003.
- S. E. L. Mirski, J. H. Gerlach, and S. P. C. Cole, "Multidrug resistance in a human small cell lung cancer cell line selected in Adriamycin", Cancer Res., Vol. 47, pp. 2594-2598, 1987.
- D. R. Hipfner, R. G. Deeley, and S. P. C. Cole, "Structural, mechanistic and clinical aspects of MRP1", Biochim. Biophys. Acta, Vol. 1461, pp. 359-376, 1999. https://doi.org/10.1016/S0005-2736(99)00168-6
- E. M. Leslie, R. G. Deeley, and S. P. C. Cole, "Toxicological relevance of the multidrug resistance protein 1, MRP1 (ABCC1) and related transporters", Toxicology, Vol. 167, 3-23, 2001. https://doi.org/10.1016/S0300-483X(01)00454-1
- H. Kusuhara, and Y. Sugiyama, "ATP-binding cassette, subfamily G (ABCG family)", Pflugers Arch., Vol. 453, pp. 735-744, 2007. https://doi.org/10.1007/s00424-006-0134-x
- L. A. Doyle, W. D. Yang, L.V. Abruzzo, T. Krogmann, Y. Gao, A. K. Rishi, and D. D. Ross, "A multidrug resistance transporter from human MCF-7 breast cancer cells", Proc. Natl. Acad. Sci. U. S. A., Vol. 95, pp. 15665-15670, 1998. https://doi.org/10.1073/pnas.95.26.15665
- T. Litman, M. Brangi, E. Hudson, P. Fetsch, A. Abati, D. D. Ross, K. Miyake, J. H. Resau, and S. E. Bates, "The multidrug-resistant phenotype associated with overexpression of the new ABC halftransporter, MXR (ABCG2)", J. Cell. Sci. Vol. 113, pp. 2011-2021, 2000.
- S. G. Aller, J. Yu, A. Ward, Y. Weng, S. Chittaboina, R. Zhuo, P. M. Harrell, Y. T. Trinh, Q. Zhang, I. L. Urbatsch and G. Chang, "Structure of P-glycoprotein Reveals a Molecular Basis for Poly-Specific Drug Binding", Science, Vol. 323, pp. 1718-1722, 2009. https://doi.org/10.1126/science.1168750
- R. J. P. Dawson, and K.P. Locher, "Structure of a bacterial multidrug ABC transporter", Nature, Vol. 443, pp. 180-185, 2006. https://doi.org/10.1038/nature05155
- U. A. Germann, T. C. Chambers, S. V. Ambudkar, T. Licht, C. O. Cardarelli, I. Pastan, and M. M. Gottesman, "Characterization of phosphorylation-defective mutants of human P-glycoprotein expressed in mammalian cells", J. Biol. Chem., Vol. 271, pp. 1708-1716, 1996. https://doi.org/10.1074/jbc.271.3.1708
- H. R. Goodfellow, A. Sardini, S. Ruetz, R. Callaghan, P. Gros, P. A. McNaughton, and C. F. Higgins, "Protein kinase C-mediated phosphorylation does not regulate drug transport by the human multidrug resistance P-glycoprotein", J. Biol. Chem., Vol. 271, pp. 13668-13674, 1996. https://doi.org/10.1074/jbc.271.23.13668
- S. P. Hardy, H. R. Goodfellow, M. A. Valverde, D. R. Gill, V. Sepúlveda, and C. F. Higgins, "Protein kinase C-mediated phosphorylation of the human multidrug resistance P-glycoprotein regulates cell volume-activated chloride channels", EMBO J., Vol. 14, pp. 68-75, 1995.
- T. Tsuruo, H. Iida, S. Tsukagoshi, and Y. Sakurai, "Enhancement of vincristine- and adriamycininduced cytotoxicity by verapamil in P388 leukemia and its sublines resistant to vincristine and Adriamycin", Biochem. Pharmacol., Vol. 31, pp. 3138-3140, 1982. https://doi.org/10.1016/0006-2952(82)90097-1
- H. Thomas, andH. M. Coley, "Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting P glycoprotein", Cancer Control, Vol. 10, pp. 159-165, 2003. https://doi.org/10.1177/107327480301000207
- J. Robert and C. Jarry, "Multidrug resistance reversal agents", J. Med. Chem., Vol. 46, pp. 4805-4817, 2003. https://doi.org/10.1021/jm030183a
- R. Krishna and L. D. Mayer, "Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs", Eur. J. Pharm. Sci., Vol. 11, pp. 265-283, 2000. https://doi.org/10.1016/S0928-0987(00)00114-7
- M. Roe, A. Folkes, P. Ashworth, J. Brumwell, L. Chima, S. Hunjan, I. Pretswell, W. Dangerfield, H. Ryder, and P. Charlton, "Reversal of P-glycoprotein mediated multidrug resistance by novel anthranilamide derivatives", Bioorg. Med. Chem. Lett., Vol. 9, pp. 595-600, 1999. https://doi.org/10.1016/S0960-894X(99)00030-X
- V. Jekerle, W. Klinkhammer, D. A. Scollard, K. Breitbach, R. M. Reilly, M. Piquette-Miller, and M. Weise, "In vitro and in vivo evaluation of WK-X-34, a novel inhibitor of P-glycoprotein and BCRP, using radio imaging techniques", Int. J. Cancer., Vol. 119, pp. 414-422, 2006. https://doi.org/10.1002/ijc.21827
- H. Muller, W. Klinkhammer, C. Globisch, M. U. Kassack, I. K. Pajeva, and M. Wiese. "New functional assay of P-glycoprotein activity using Hoechst 33342", Bioorg. Med. Chem., Vol. 15, pp. 7470-7479, 2007. https://doi.org/10.1016/j.bmc.2007.07.024
- H. Muller, I. K. Pajeva, C. Globisch, and M. Wiese, "Functional assay and structure-activity relationships of new third-generation P-glycoprotein inhibitors", Bioorg. Med. Chem., Vol. 16, pp. 2448-2462, 2008. https://doi.org/10.1016/j.bmc.2007.11.057
- K. Ueda, Y. Taguchi, and M. Morishima, "How does P-glycoprotein recognize its substrates", Semin. Cancer Biol., Vol. 8, pp. 151-159, 1997. https://doi.org/10.1006/scbi.1997.0066
- Z. E. Sauna, and S. V. Ambudkar, "Evidence for a requirement for ATP hydrolysis at two distinct steps during a single turnover of the catalytic cycle of human P-glycoprotein", Proc. Natl. Acad. Sci., Vol. 97, pp. 2515-2520, 2000. https://doi.org/10.1073/pnas.97.6.2515
- M. Varma, Y. Ashokraj, C. S. Dey, and R. Panchagnula, "P-glycoprotein inhibitors and their screening: a perspective from bioavailability enhancement", Pharmacol. Res., Vol. 48, pp. 347-359, 2003. https://doi.org/10.1016/S1043-6618(03)00158-0
- S. V. Ambudkar, I. W. Kim, and Z. E. Sauna, "The power of the pump: mechanisms of action of P-glycoprotein (ABCB1)", Eur. J. Pharm. Sci., Vol. 27, pp. 392-400, 2006. https://doi.org/10.1016/j.ejps.2005.10.010
- V. R. Tandon, B. Kapoor, G. Bano, S. Gupta, Z. Gillani, S. Gupta, and D. Kour, "Pglycoprotein: Pharmacological relevance", Indian J. Pharmacol., Vol. 38, pp. 13-24, 2006. https://doi.org/10.4103/0253-7613.19847
- K. R. Narayana, M. S. Reddy, M. R. Chaluvadi, and D. R. Krishna, "Bioflavonoids classification, pharmacological, biochemical effects and therapeutic potential", Ind. J. Pharmacol., Vol. 33, pp. 2-16, 2001.
- Z. E. Sauna, and S. V. Ambudkar, "Evidence for a requirement for ATP hydrolysis at two distinct steps during a single turnover of the catalytic cycle of human P-glycoprotein", Proc. Natl. Acad. Sci., Vol. 97, pp. 2515-2520, 2000. https://doi.org/10.1073/pnas.97.6.2515
- Z. E. Sauna, M. M. Smith, M. Muller, K. M. Kerr, and S. V. Ambudkar, "The mechanism of action of multidrug-resistance-linked P-glycoprotein J", Bioener. Biomemb., Vol. 33, pp. 481-491, 2001. https://doi.org/10.1023/A:1012875105006
- R. Regev, Y. G. Assaraf, and G. D. Eytan, "Membrane fluidization by ether, other anesthetics, and certain agents abolishes Pglycoprotein ATPase activity and modulates efflux from multidrug-resistant cells", Eur. J. Biochem., Vol. 25, pp. 18-24, 1999.
- K. Sachs-Barrable, A. Thamboo, S. D. Lee, and K. M. Wasan, "Lipid excipients Peceol and Gelucire 44/14 decrease P-glycoprotein mediated efflux of rhodamine 123 partially due to modifying P-glycoprotein protein expression within Caco-2 cells", J. Pharm. Pharm. Sci., Vol. 10, pp. 319-331, 2007.
- A. Boumendjel, A. Di Pietro, C. Dumontet, and D. Barron, "Recent advances in the discovery of flavonoids and analogues with high affinity binding to P-glycoprotein responsible for cancer cell multidrug resistance", Med. Res. Rev., Vol. 22, pp. 512-529, 2002. https://doi.org/10.1002/med.10015
Cited by
- Quantitative Structure–Activity Relationships for the Flavonoid-Mediated Inhibition of P-Glycoprotein in KB/MDR1 Cells vol.24, pp.9, 2012, https://doi.org/10.3390/molecules24091661